Table 3.
Oncological outcomes before and after propensity score matching analysis
| Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
| ODG | LDG | p | ODG | LDG | p | |
| n = 45 | n = 46 | n = 34 | n = 34 | |||
| T-stage (n, %) | 0.743 | 0.589 | ||||
| pT1 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| pT2 | 13 (28.9%) | 12 (26.1%) | 10 (29.4%) | 9 (26.5%) | ||
| pT3 | 17 (37.8%) | 21 (45.7%) | 13 (38.2%) | 17 (50.0%) | ||
| pT4 | 15 (33.3%) | 13 (28.3%) | 11 (32.4%) | 8 (23.5%) | ||
| N-stage (n, %) | 0.578 | 1.000 | ||||
| pN0 | 7 (15.6%) | 12 (26.1%) | 7 (20.6%) | 7 (20.6%) | ||
| pN1 | 14 (31.1%) | 16 (34.8%) | 8 (23.5%) | 8 (23.5%) | ||
| pN2 | 9 (20.0%) | 8 (17.4%) | 9 (26.5%) | 9 (26.5%) | ||
| pN3 | 15 (33.3%) | 10 (21.7%) | 10 (29.4%) | 10 (29.4%) | ||
| M-stage | 1.000 | 1.000 | ||||
| pM0 | 45 (100%) | 46 (100%) | 34 (100%) | 34 (100%) | ||
| pM1 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| Retrieved nodes (n) | 0.281 | 0.849 | ||||
| (mean ± SD) | 27.6 ± 16.3 | 24.6 ± 10.3 | 26.1 ± 12.3 | 26.0 ± 10.6 | ||
| (median, range) | 24.0 (2–94) | 24.5 (5–54) | 24.0 (2–63) | 24.5 (9–54) | ||
| Positive nodes (mean ± SD) | 8.8 ± 12.8 | 5.3 ± 6.2 | 0.102 | 7.2 ± 7.0 | 5.6 ± 5.9 | 0.452 |
| Node ratio (mean ± SD) | 0.3 ± 0.3 | 0.2 ± 0.2 | 0.063 | 0.3 ± 0.3 | 0.2 ± 0.2 | 0.216 |
| R0 resection (n, %) | 43 (95.6%) | 45 (97.8%) | 0.985 | 33 (94.4%) | 34 (100%) | 0.473 |
| TNM stage (n, %) | ||||||
| IA | 0 (0.0%) | 0 (0.0%) | 0.241 | 0 (0.0%) | 0 (0.0%) | 0.392 |
| IB | 2 (4.4%) | 4 (8.7%) | 2 (5.9%) | 2 (5.9%) | ||
| IIA | 6 (13.3%) | 9 (19.6%) | 5 (14.7%) | 6 (17.6%) | ||
| IIB | 8 (17.8%) | 15 (32.6%) | 5 (14.7%) | 12 (35.3%) | ||
| IIIA | 10 (22.2%) | 4 (8.7%) | 8 (23.5%) | 4 (11.8%) | ||
| IIIB | 10 (22.2%) | 7 (15.2%) | 7 (20.6%) | 6 (17.6%) | ||
| IIIC | 9 (20.0%) | 7 (15.2%) | 7 (20.6%) | 4 (11.8%) | ||
| IV | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||